TriangleRuxolitinib + CHOP (NCT07278856)
Ruxolitinib + CHOP trial for Untreated Nodal T Follicular Helper Cell Lymphoma (NCT07278856). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with nodal T follicular helper cell lymphoma, a type of T cell lymphoma, who have not been treated yet.
The idea: add ruxolitinib, a pill that blocks a protein called Janus kinase, to standard CHOP chemotherapy. Blocking it may help keep cancer cells from growing.
The study looks at safety, the best dose of ruxolitinib, and how well the combination works.
This phase 1 study plans 20 patients. At City of Hope in Duarte, California, Christina Poh leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.